Serum or Plasma for Quantification of Direct Oral Anticoagulants?

Direct oral anticoagulants (DOACs) are increasingly replacing vitamin K antagonists for prevention of stroke in patients with atrial fibrillation, partly owing to the lack of a need for routine monitoring. Therapeutic drug monitoring may still be warranted under certain circumstances. It is generally assumed that serum and plasma can be interchangeably employed for this purpose. The aim of this study was to investigate possible differences between the serum, citrate-plasma, and ethylenediaminetetraacetic acid (EDTA)-plasma concentrations of apixaban and rivaroxaban in a larger patient group and their relation to factor X measurements.
Plasma and serum samples were drawn during the same venipuncture from patients treated with apixaban or rivaroxaban. Drug levels were measured using ultrahigh-performance liquid chromatography combined with tandem mass spectrometry. Three sample matrices were obtained from eight healthy volunteers for measurement of factor X antigen and activity.
Mean concentrations of apixaban and rivaroxaban were 16.8% and 36.6% higher in the serum than in citrate-plasma, respectively (both p<0.001). The corresponding differences in serum vs. EDTA-plasma were 4.5% for apixaban and 13.1% for rivaroxaban (both p<0.001). Factor X antigen measurements in citrate-plasma, EDTA-plasma, serum with clot activator, and serum without additives yielded comparable results, and factor X activity was significantly higher in serum than in plasma.
Apixaban and rivaroxaban concentrations were significantly higher in the serum than in plasma. The difference was more pronounced with rivaroxaban, and was larger between serum and citrate-plasma than between serum and EDTA-plasma. Higher factor X activity in serum may explain the observed concentration differences. The choice of matrix is, thus, important when interpreting therapeutic drug monitoring results as well as in research involving analyses of DOACs. The authors recommend citrate-plasma as the preferred matrix.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.